Salekzamani Shabnam, Bavil Abolhassan Shakeri, Mehralizadeh Hossein, Jafarabadi Mohammad Asghari, Ghezel Aymaral, Gargari Bahram Pourghassem
Talented Students Center, Student Research Committee, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Endocrine. 2017 Jul;57(1):51-59. doi: 10.1007/s12020-017-1317-2. Epub 2017 May 16.
Metabolic syndrome may predispose to cardiovascular diseases. Since, in recent studies, vitamin D is advocated for cardioprotective roles, this study was designed to investigate the effects of vitamin D supplementation on proatherogenic inflammatory markers and common carotid intima media thickness in subjects with metabolic syndrome.
This randomized double blind clinical trial was conducted in Tabriz, Iran. Eligible subjects (n = 80) with metabolic syndrome were recruited thorough advertisement and randomized to receive either vitamin D (50,000 IU/week) or matching placebo for 16 weeks. Interlukin-6, high sensitivity C-reactive protein, vascular cell adhesion molecule-1, E-selectin, and common carotid intima media thickness were measured at the beginning and end of the study. The study was registered at http://www.irct.ir (code: IRCT201409033140N14).
Sixteen weeks supplementation with vitamin D increased median of serum 25-hydroxy vitamin D [25(OH)D] and mean calcium levels (p < 0.001) in the intervention group. There was also a significant difference in parathyroid hormone level at the end of the study (p < 0.001). Vitamin D treatment reduced IL-6 level after 16 weeks (p = 0.027). Compared to baseline, vascular cell adhesion molecule-1 and E-selectin levels decreased significantly in vitamin D treated subjects; however, there were no significant differences between two groups. No effect of vitamin D supplementation was observed in either common carotid intima media thickness or high sensitivity C-reactive protein concentrations at the end of the study (p > 0.05).
Vitamin D supplementation improved some proatherogenic inflammatory markers in subjects with metabolic syndrome. No changes of high sensitivity C-reactive protein and carotid intima media thickness were shown after 16 weeks.
代谢综合征可能易患心血管疾病。鉴于近期研究提倡维生素D具有心脏保护作用,本研究旨在探讨补充维生素D对代谢综合征患者促动脉粥样硬化炎症标志物及颈总动脉内膜中层厚度的影响。
本随机双盲临床试验在伊朗大不里士进行。通过广告招募了80名符合条件的代谢综合征患者,并随机分为两组,分别接受维生素D(50,000 IU/周)或匹配的安慰剂,为期16周。在研究开始和结束时测量白细胞介素-6、高敏C反应蛋白、血管细胞黏附分子-1、E选择素以及颈总动脉内膜中层厚度。该研究已在http://www.irct.ir注册(代码:IRCT201409033140N14)。
干预组补充维生素D 16周后,血清25-羟基维生素D[25(OH)D]中位数及血钙水平升高(p<0.001)。研究结束时甲状旁腺激素水平也有显著差异(p<0.001)。维生素D治疗16周后白细胞介素-6水平降低(p=0.027)。与基线相比,维生素D治疗组患者血管细胞黏附分子-1和E选择素水平显著降低;然而,两组之间无显著差异。研究结束时,补充维生素D对颈总动脉内膜中层厚度或高敏C反应蛋白浓度均无影响(p>0.05)。
补充维生素D可改善代谢综合征患者的一些促动脉粥样硬化炎症标志物。16周后高敏C反应蛋白及颈动脉内膜中层厚度无变化。